UNSPSC 51372112: Codeine hydrobromide

This classification denotes an opiate with the molecular formula C18H21NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8HOK0TIN61, chemically known as morphinan-6-alpha-ol, 7,8-didehydro-4,5-alpha-epoxy-3-methoxy-17-methyl-, hydrobromide but more generally known as codeine hydrobromide, which bears US NIH Compound Identifier 5464192. European Medicines Agency schedules Codeine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13426MIG.

Most nations, for tariff and trade purposes, schedule codeine hydrobromide under HS 29391100. As of Q4 2014, CODEINE HYDROBROMIDE remains US FDA's Preferred Term for this commodity. SMILES: CN1CC[C@]23C4C5CCC(C4O[C@H]2[C@H](C=C[C@H]3[C@H]1C5)O)OC.BR.

UNSPSC 51372112 Codeine hydrobromide is a Commodity code that in recent state and local procurement activity covers acquisition of pharmaceutical products—primarily naloxone, generic multi-source pharmaceuticals, and over-the-counter products—by health departments, cooperative purchasing alliances, and state health agencies supporting community health initiatives, pharmacy benefit programs, and emergency response systems. The work involves sourcing finished pharmaceutical products with specific National Drug Codes, managing supply chain compliance including FDA requirements and Drug Supply Chain Security Act certification, arranging distribution through authorized wholesalers or direct delivery, and meeting regulatory standards such as current Good Manufacturing Practices and expiration-date requirements. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and the Texas Health and Human Services Commission appear as active buyers in the recent pipeline.

Recent activity spans Florida, Minnesota, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building (response deadline July 26, 2023). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for the Therapeutic Pharmacy Initiative. MMCAP issued RFP S1070000015802 in January 2026 (response deadline March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, requiring vendors to certify cGMP and DSCSA compliance, maintain relationships with authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., and submit detailed NDC-level product information with pricing in flat, net, or WAC-minus formats.